Analysis of efficacy to diagnose differentiation of hepatocellular carcinoma using contrast-enhanced ultrasonography with Sonazoid

Analysis of efficacy to diagnose differentiation of hepatocellular carcinoma using contrast-enhanced ultrasonography with Sonazoid - Efficacy to diagnose differentiation of hepatocellular carcinoma using contrast-enhanced ultrasonography

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015393

Enrollment

Registered

2014-10-10

Start date

2008-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Microbubble contrast agents

Sonazoid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who were planned to receive percutaneous tumor biopsy suspected of hepatocellular carcinoma by ultrasonography, intravenous contrast-enhanced computed tomography, or magnetic resonance imaging 2. Patients who were diangnosed pathologically as hepatocellular carcinoma, adenoid hyperplasia (dysplastic nodule), or regenerative nodule 3. Having received adequate explanation of the contents of the trial and given their written consent

Exclusion criteria

Exclusion criteria: 1. Egg allergy 2. Severe lung disease 3. Severe heart disease 4. Determined to be ineligible by the physician in charge for any other reason

Design outcomes

Primary

Measure	Time frame
To analyse relationships with pathological findings of hepatocellular carcinoma and findings in early phase, such as hypervascular, isovascular, or hypovascular using contrast-enhanced ultrasonography	—

Countries

Japan

Contacts

Public ContactHitoshi Maruyama

Chiba University Graduate School of Medicine Department of Gastroenterology and Nephrology

maru-cib@umin.ac.jp043-226-2083

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026